2013-03-08 18:09:02 -

REGULATED INFORMATION

GHENT,   Belgium,   8 March   2013 -   Ablynx  [Euronext  Brussels:  ABLX],  the
biopharmaceutical   company   focused   on  the  discovery  and  development  of
Nanobodies®,   announces  today  that  the  closing  of  its  private  placement
("Accelerated  Bookbuild Offering"/"ABO")  took place  on 5 March  2013
and as a
result, Ablynx issued 4,377,919 new shares. In addition, 348,400 new shares were
issued that same day as a result of the exercise of 641,800 warrants.

Ablynx  NV also publishes  the following information  in accordance with article
15 of the Law of 2 May 2007 on   the publication of major shareholdings in issuers
whose  shares are admitted  to trading on  a regulated market (the "Transparency
Law"):

+----------------------------------------------------+----------------+
| Total amount of the share capital:                 | €90,653,858.30 |
+----------------------------------------------------+----------------+
| Total number of securities carrying voting rights: | 48,505,516     |
+----------------------------------------------------+----------------+
| Total number of voting rights (denominator):       | 48,505,516     |
+----------------------------------------------------+----------------+

Ablynx  NV  has  in  total  3,904,145 outstanding  warrants, of which 1,657,700
warrants  give the holder the  right to a total  of 828,850 shares (two warrants
giving the right to subscribe to one share) and of which 2,246,445 warrants give
the  holder the  right to  a total  of 2,246,445 shares  (one warrant giving the
right to subscribe to one share). The acceptance and issuing of 467,500 warrants
(one  warrant giving the right to subscribe  to one share) is pending. The total
number  of voting rights, which  can be acquired as  a result of the exercise of
the outstanding warrants, amounts to 3,075,295.

In addition, Ablynx NV announces, in accordance with article 14 of the Law of 2
May  2007 on the publication of major  shareholdings in issuers whose shares are
admitted  to trading on a regulated market (the "Transparency Law"), that it has
received  the following  transparency notifications  between 28 February  and 7
March 2013.

+----------------------------+-----------------------+-------------------------+
|Notifier(s)                 |Number of voting rights|Percentage    of   voting|
|                            |                       |rights                   |
+----------------------------+-----------------------+-------------------------+
|Gimv  NV,  Adviesbeheer Gimv|       5,825,939       |         12.01%          |
|Life       Sciences      NV,|                       |                         |
|Adviesbeheer    Gimv    Life|                       |                         |
|Sciences 2004 NV and Biotech|                       |                         |
|Fonds Vlaanderen NV(1)      |                       |                         |
+----------------------------+-----------------------+-------------------------+
|Sofinnova Partners SAS      |       4,675,587       |          9.63%          |
+----------------------------+-----------------------+-------------------------+

(1)  Gimv NV controls  Adviesbeheer Gimv Life  Sciences NV and Adviesbeheer Gimv
Life Sciences 2004 NV. Gimv NV (2,463,320 voting rights), Adviesbeheer Gimv Life
Sciences  NV (0 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV (433,745
voting  rights) and  Biotech Fonds  Vlaanderen NV  (2,928,874 voting rights) are
acting  in  mutual  agreement.  The  Flemish  Region  in Belgium is the ultimate
shareholder of  Biotech Fonds Vlaanderen NV.

The full versions of the transparency notifications are available on the website
of Ablynx (www.ablynx.com - investor relations).


About Ablynx

Ablynx  is a biopharmaceutical company engaged  in the discovery and development
of  Nanobodies(®), a novel class of  therapeutic proteins based on single-domain
antibody   fragments,   for   a  range  of  serious  human  diseases,  including
inflammation,  haematology, oncology  and pulmonary  disease. Today, the Company
has  approximately 25 programmes in the pipeline and five Nanobodies at clinical
development  stage. Ablynx has on-going  research collaborations and significant
partnerships with major pharmaceutical companies including Boehringer Ingelheim,
Merck  Serono, Novartis and Merck  & Co. The Company  is headquartered in Ghent,
Belgium.

More information can be found on www.ablynx.com.



For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330
e:  ablynx@mcomgroup.com


press release in pdf: 
 hugin.info/137912/R/1684075/551329.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Ablynx via Thomson Reuters ONE
[HUG#1684075]